Related Experiment Videos
Detection of hepatic malignancies using Mn-DPDP (manganese dipyridoxal diphosphate) hepatobiliary MRI contrast agent
S W Young1, B Bradley, H H Muller
1Department of Diagnostic Radiology, Stanford University School of Medicine, CA 94305.
Abstract:
A new hepatobiliary contrast agent (Mn-DPDP) was used in the detection of liver metastases in six rabbits with seven hepatic V2 carcinomas. This contrast agent is derived from pyridoxyl-5-phosphate which is biomimetically designed to be secreted by the hepatocyte. After Mn-DPDP administration, a 105% increase in liver signal to noise was obtained using a 200/20 (TR/TE) pulsing sequence, and a 62% decrease in intensity was observed using a 1200/60 pulsing sequence. Liver V2 carcinoma contrast enhancement increased 427% using the 200/20 pulsing sequence and 176% using the 1200/60 pulsing sequence. Four of seven V2 carcinomas were not detectable prior to the administration of Mn-DPDP (50 mumol/kg). Two neoplasms were only detectable in retrospect (after Mn-DPDP) on the 1200/60 sequence. The smallest neoplasms detected in this study were 1-4 mm. Mn-DPDP appears to be a promising MRI contrast agent.
Insights
A novel hepatobiliary MRI contrast agent, Mn-DPDP, significantly improved the detection of liver metastases in rabbits. This agent enhanced tumor visibility, enabling the identification of small neoplasms previously undetectable.
Area of Science:
- Hepatobiliary imaging
- Magnetic Resonance Imaging (MRI)
Background:
- Liver metastases detection remains a clinical challenge.
- Development of targeted hepatobiliary contrast agents is crucial for improved diagnostic accuracy.
Purpose of the Study:
- To evaluate the efficacy of a novel hepatobiliary MRI contrast agent, Mn-DPDP, in detecting liver metastases.
- To assess the impact of Mn-DPDP on liver and tumor signal-to-noise ratios using different MRI sequences.
Main Methods:
- Six rabbits with induced hepatic V2 carcinomas were studied.
- Mn-DPDP (50 μmol/kg) was administered intravenously.
- MRI scans were performed using 200/20 (TR/TE) and 1200/60 (TR/TE) pulsing sequences before and after contrast administration.
Main Results:
- Mn-DPDP administration resulted in a 105% increase in liver signal-to-noise ratio (SNR) with the 200/20 sequence and a 62% decrease with the 1200/60 sequence.
- Liver V2 carcinoma enhancement increased by 427% (200/20 sequence) and 176% (1200/60 sequence).
- Four of seven V2 carcinomas were undetectable before Mn-DPDP; two were detected only in retrospect, with the smallest detected neoplasms measuring 1-4 mm.
Conclusions:
- Mn-DPDP demonstrates significant potential as an MRI contrast agent for detecting liver metastases.
- The agent enhances tumor conspiciousness, improving the detection of small hepatic neoplasms.
- Further research is warranted to explore its clinical utility in human patients.